Prostate Cancer Screening - 26/04/19
, Fereshteh Gerayli, MDRésumé |
Whether to screen for prostate cancer in aging men is a topic that is fairly well researched, but recommendations are controversial, because the evidence supporting any recommendation is equivocal. The evidence clearly does not support routine screening of all average-risk men, but for men aged 55 to 69 years, either not routinely screening, or engaging each man in shared decision making for his individual preference on screening, is reasonable and consistent with the evidence. Many organizations, including the American Cancer Society, have not yet reassessed their guidelines, in response to the US Preventative Services Task Force revised guideline.
Le texte complet de cet article est disponible en PDF.Keywords : Prostate cancer, Prostate cancer screening, PSA, PSA screening, Prostate cancer treatment, Overdiagnosis
Plan
| Disclosure Statement: The authors have nothing to disclose. |
Vol 46 - N° 2
P. 257-263 - juin 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
